KRAS and lung carcinoma: Interestingly, a combination of IGF-IR and MEK inhibitors was recently reported to result in significant inhibition of K-Ras-mutant lung cancer lines and also improve effectiveness in two mouse models of K-Ras-driven lung cancer [32].